HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric adenocarcinoma

被引：0
|
作者：
Zimin Liu
Mingpeng Shi
Xiaoxiao Li
Shanai Song
Ning Liu
Haiwei Du
Junyi Ye
Haiyan Li
Zhou Zhang
Lu Zhang
机构：
[1] The Affiliated Hospital of Qingdao University,Oncology Department
[2] Burning Rock Biotech,Operating Room of Neurosurgery
[3] The Affiliated Hospital of Qingdao University,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2021年 / 147卷
关键词：
Copy number; Resectable gastric adenocarcinoma; Survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1315 / 1324
页数：9
相关论文
共 50 条
  • [1] HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric adenocarcinoma
    Liu, Zimin
    Shi, Mingpeng
    Li, Xiaoxiao
    Song, Shanai
    Liu, Ning
    Du, Haiwei
    Ye, Junyi
    Li, Haiyan
    Zhang, Zhou
    Zhang, Lu
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (05) : 1315 - 1324
  • [2] HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric cancer
    Liu, Z.
    Shi, M.
    Song, S.
    Gao, J.
    Li, H.
    Han-Zhang, H.
    Ye, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [3] HER2 copy number on FISH as a predictor of disease severity in HER2-breast cancer
    Abedin, S.
    Kruse, M.
    Brufsky, A.
    Bhargava, R.
    CANCER RESEARCH, 2013, 73
  • [4] Neratinib Boosts Invasive Disease-Free Survival in HER2-Positive Breast Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (03) : 195 - 195
  • [5] HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
    Kaito, Akio
    Kuwata, Takeshi
    Tokunaga, Masanori
    Shitara, Kohei
    Sato, Reo
    Akimoto, Tetsuo
    Kinoshita, Takahiro
    WORLD JOURNAL OF CLINICAL CASES, 2019, 7 (15) : 1964 - 1977
  • [6] HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
    Akio Kaito
    Takeshi Kuwata
    Masanori Tokunaga
    Kohei Shitara
    Reo Sato
    Tetsuo Akimoto
    Takahiro Kinoshita
    World Journal of Clinical Cases, 2019, (15) : 1964 - 1977
  • [7] Targeted therapies of HER2-positive gastric adenocarcinoma
    Schulze, Arik Bernard
    Kerkhoff, Andrea
    Lenz, Georg
    Kessler, Torsten
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S177 - S180
  • [8] Docetaxel/trastuzumab improves disease-free survival in early HER2-positive breast cancer
    不详
    ONCOLOGY-NEW YORK, 2006, 20 (05): : 475 - 475
  • [9] HER2-positive gastric cancer identified by serum HER2: A case report
    Saito, Mayuko
    Kawakami, Yujiro
    Yamashita, Kentaro
    Nasuno, Hiroshi
    Ishimine, Yu
    Fukuda, Koichiro
    Isshiki, Hiroyuki
    Suzuki, Ryo
    Arimura, Yoshiaki
    Shinomura, Yasuhisa
    ONCOLOGY LETTERS, 2016, 11 (06) : 3575 - 3578
  • [10] HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
    Hosonaga, Mari
    Arima, Yoshimi
    Sampetrean, Oltea
    Komura, Daisuke
    Koya, Ikuko
    Sasaki, Takashi
    Sato, Eiichi
    Okano, Hideyuki
    Kudoh, Jun
    Ishikawa, Shumpei
    Saya, Hideyuki
    Ishikawa, Takashi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (08)
12345